Disease relevance of D01733

• Histopathological evaluation showed no signs of retinal toxicity to anecortave acetate delivery alone or in combination with carboplatin [1].
• Anecortave acetate as single and adjuvant therapy in the treatment of retinal tumors of LH(BETA)T(AG) mice [1].
• PURPOSE: To evaluate the antiangiogenic potential of topical ophthalmic formulations of the novel angiostatic steroids AL-3789 and AL-4940, using a rabbit model of corneal neovascularization [2].
• This study was designed to test the capacity of an angiostatic steroid, anecortave acetate, to inhibit retinal neovascularization using a rat model of ROP and to investigate the mechanism of the effect [3].
• Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes [4].

High impact information on D01733

• CONCLUSIONS: Anecortave acetate, as monotherapy or as adjuvant therapy, significantly controlled tumor burden in a murine model of retinoblastoma [1].
• METHODS: Group A: Ten-week-old, LH(BETA)T(AG) mice received a single subconjunctival injection of anecortave acetate (1200, 600, 300, and 150 microg) delivered to right eyes only [1].
• Tumor burden was significantly decreased when anecortave acetate and carboplatin were combined [1].
• PURPOSE: To evaluate the tumor control efficacy of the antiangiogenic agent anecortave acetate as single and combined therapy, in retinal tumor reduction using the LH(BETA)T(AG) mouse model of retinoblastoma [1].
• Tumor inhibition was presumably due to the angiostatic properties of anecortave acetate because the compound did not affect tumor cell proliferation in vitro [5].

Chemical compound and disease context of D01733

• Clinical Safety Profile of Posterior Juxtascleral Depot Administration of Anecortave Acetate 15 mg Suspension as Primary Therapy or Adjunctive Therapy with Photodynamic Therapy for Treatment of Wet Age-Related Macular Degeneration [6].

Biological context of D01733

• Pharmacokinetics and metabolism of anecortave acetate in animals and humans [7].
• CONCLUSION:: The results suggest that a posterior juxtascleral injection of anecortave acetate reduces capillary permeability in patients with RAP [8].
• RESULTS: Six months after a single treatment, visual acuity (mean change from baseline logMAR values) was significantly better (P = 0.003) after anecortave acetate 15 mg than placebo [9].

Anatomical context of D01733

• Studies show that posterior juxtascleral depot administration of anecortave acetate is an effective, minimally invasive method of delivering this drug to the choroid and retina [7].
• Two of the most potent angiostatic steroids, AL-3789 and AL-4940, were evaluated for glucocorticoid-mediated antiinflammatory activity in the in vitro U937 cell model of LPS-induced IL-1 induction and found to be devoid of glucocorticoid activity [10].

Associations of D01733 with other chemical compounds

• Coded formulations of the control vehicle or the following test agents were administered in prevention and intervention treatment protocols: 1% formulations of AL-3789, AL-4940, and cortisol acetate as a positive drug control [2].
• The Digital Angiography Reading Center (DARC) Role in the Anecortave Acetate Clinical Trials [11].
• Other treatments discussed are anecortave acetate, triamcinolone acetonide, bevacizumab, rostaporfin (SnET2), squalamine, and transpupillary thermotherapy [12].
• METHODS: Control eye data from six AMD studies (Macular Photocoagulation Study, Subfoveal Surgery Trial, Photodynamic Therapy [TAP] With Visudyne, pegaptanib trial for neovascular AMD, anecortave acetate trial, and 360 degree Macular Translocation Study) were plotted on a double reciprocal plot of 1/(Letters Lost) vs 1/(Months After Enrollment) [13].
• Subconjunctival injection of FMPA, anecortave acetate or betamethasone was performed once just after the photocoagulation (on day 0) [14].

Gene context of D01733

• ANECORTAVE ACETATE FOR THE TREATMENT OF IDIOPATHIC PERIFOVEAL TELANGIECTASIA: A Pilot Study [15].

Analytical, diagnostic and therapeutic context of D01733

• On days 21 and 28 the net tumor weight of the AL-3789-treated animals was 40% to 30% of controls (P < 0.05) [5].
• Three doses of AL-3789 (0.01%, 0.1%, and 1%) were also evaluated in a prevention treatment protocol [2].
• The Anecortave Acetate and photodynamic therapy (PDT) with verteporfin Combination Trial enrolled 136 patients randomized to PDT with verteporfin followed by a single depot administration of anecortave acetate (15 mg or 30 mg) or vehicle [16].
• Results of initial studies led to the design of a new cannula that could effectively deliver anecortave acetate as a posterior juxtascleral depot, providing adequate retinal and choroidal drug concentrations for up to 6 months after a single administration [7].
• METHODS: Detailed ophthalmic examinations, physical examinations, and adverse event reporting were used to characterize the clinical safety of anecortave acetate 15 mg and were monitored by an Independent Safety Committee. RESULTS: Anecortave acetate 15 mg was safe and well tolerated in the overall patient population [6].

References